Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 1. Schematic representation of the MasSpec Pen system and operational steps. Schematic representation of the MasSpec Pen system and operational steps.

Published byDieter Krämer Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 1. Schematic representation of the MasSpec Pen system and operational steps. Schematic representation of the MasSpec Pen system and operational steps."— Presentation transcript:

1 Fig. 1. Schematic representation of the MasSpec Pen system and operational steps.
Schematic representation of the MasSpec Pen system and operational steps. (A) The pen-sized handheld device is directly integrated into a laboratory-built MS interface through PTFE tubing. The integrated MS interface houses the pinch valves, microcontroller, and tubing to connect the system to the mass spectrometer inlet. The system is triggered by the user through a foot pedal. (B) The MasSpec Pen (handheld device) is designed with a PDMS tip and three PTFE conduits, which provide incoming water (1) and gas (2) to the tip and an outgoing conduit for the water droplet (3). (C) The tip contacts the tissue for analysis. Inset shows the three conduits (1 to 3) and solvent reservoir (4) within the tip. When the system is triggered (t = 0 s) by using the foot pedal, the syringe pump delivers a controlled volume of water to the reservoir. The discrete water droplet interacts with the tissue to extract the molecules (t = 2 s). After 3 s of extraction, the vacuum and the gas conduits are concomitantly opened (arrows) to transport the droplet from the MasSpec Pen to the mass spectrometer through the tubing system for molecular analysis. Jialing Zhang et al., Sci Transl Med 2017;9:eaan3968 Published by AAAS

Download ppt "Fig. 1. Schematic representation of the MasSpec Pen system and operational steps. Schematic representation of the MasSpec Pen system and operational steps."

Similar presentations

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia by Michael Kalos, Bruce.
The Bayh-Dole Act Turns 30 by Vicki Loise, and Ashley J. Stevens Sci Transl Med Volume 2(52):52cm27-52cm27 October 6, 2010 Published by AAAS.

The Bayh-Dole Act Turns 30 by Vicki Loise, and Ashley J. Stevens Sci Transl Med Volume 2(52):52cm27-52cm27 October 6, 2010 Published by AAAS.
First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,

First-in-Human Testing of a Wirelessly Controlled Drug Delivery Microchip by Robert Farra, Norman F. Sheppard, Laura McCabe, Robert M. Neer, James M. Anderson,
Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing by Rebecca J. Leary, Isaac Kinde, Frank Diehl, Kerstin Schmidt, Chris.
Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.

Fig. 1 CSF1 is increased in blood of melanoma patients and correlates with disease progression. CSF1 is increased in blood of melanoma patients and correlates.
Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.
Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.

Fig. 5. Correlation between CD34+CD45RA−CD90+ cell dose, engraftment success, and onset of neutrophil/platelet recovery in nonhuman primates. Correlation.
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Ex vivo and in vivo function of the MeTro sealant using rat incision model of arteries. Ex vivo and in vivo function of the MeTro sealant using.

Fig. 4. Ex vivo and in vivo function of the MeTro sealant using rat incision model of arteries. Ex vivo and in vivo function of the MeTro sealant using.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 4. Hydrogel particle size and gelation mechanism.

Fig. 4. Hydrogel particle size and gelation mechanism.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
Fig. 1 Crohn’s disease association within the LRRK2 locus.

Fig. 1 Crohn’s disease association within the LRRK2 locus.
Fig. 3. Frequencies of amino acids at critical PGT121 and 10-1074 contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.

Fig. 3. Frequencies of amino acids at critical PGT121 and contact sites in the SHIV-SF162P3 challenge stock. Frequencies of amino acids at critical.
Fig. 3. 3RMR response to graded ischemia ex vivo.

Fig. 3. 3RMR response to graded ischemia ex vivo.
Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.
Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.

Fig. 2 Maraba treatment results in complete responses in the window of opportunity setting. Maraba treatment results in complete responses in the window.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Similar presentations

Ads by Google